Developer docs
API playgroundTry for free, no card

Search company profiles

Vimta Labs

Full company profile

uuid0004igb

Namestring
Vimta Labs
Legal namestring
Vimta Labs Limited
Websiteurl
vimta.com
Company typeenum
Public
Founded yearint
1984
Descriptiontext

Vimta Labs Limited is a publicly listed (NSE: VIMTALABS; BSE) Hyderabad-headquartered Contract Research and Testing Organization (CRO) founded on 17 August 1984, operating a nationwide network of accredited laboratories across pharmaceuticals, biologics, food, water, electricals & electronics, environment/health & safety, medical devices and clinical diagnostics. The company serves pharmaceutical and biopharma manufacturers with cGMP laboratory services, preclinical and clinical research support, and biologics/biosimilars testing and development (CRADS), while its food testing arm operates India's National Food Laboratory at JNPT Mumbai under a Public-Private Partnership with FSSAI and runs food labs in 8+ cities. The electricals & electronics testing business — organized by Domain (consumer electronics, avionics, automotive, military), by Test (EMI/EMC, RF, environmental reliability, physical security), and by Service Package (BIS CRS, TEC, CE Marking) — is anchored by Vimta's status as the only NABCB-accredited certification body in India for Physical Security Products under ISO/IEC 17065 and the first-in-India NABL-accredited PSP test facility. Emtac Laboratories Private Limited, acquired in 2019-20, was amalgamated into Vimta via NCLT order dated 23 January 2025 to consolidate electronics testing capacity.

Vimta earns revenue primarily through professional services (contract research and laboratory testing) billed on a quote-based, project-specific basis with pay-as-you-go cadence across enterprise field sales channels; a secondary licensing-style revenue stream comes from PSP product certification fees (application, minimum marking, audit and licence fees); and a managed-services revenue stream is generated from walk-in clinical diagnostics labs. The GTM motion combines direct regional sales personnel in 15+ Indian cities, active participation in global industry conferences (CPHI Milan, Eurotox, DCAT, CAC, Chemspec), institutional investor engagement through quarterly earnings calls, and regulatory partnerships including the FSSAI PPP. Pricing is not publicly disclosed; engagement is initiated via regional sales contacts or web inquiry forms.

In August 2024, Vimta executed and completed a Business Transfer Agreement with Thyrocare Technologies Limited, divesting its food diagnostics business to refocus on the core CRO and certification platform. For FY2025-26, Vimta reported standalone sales of Rs 407.29 crore (up 18.41% YoY) and net profit of Rs 77.51 crore (up 15.10%), with Q4 FY26 sales of Rs 109.25 crore (up 15.68%) — placing the company within India's TIC market that is projected to grow from USD 7.9 billion in 2025 to nearly USD 10.9 billion by 2034. The company has 1,001-5,000 employees, is led by Executive Chairman Dr. S. P. Vasireddi (re-appointed effective 1 July 2026), and is recognized alongside Syngene International and Tata Elxsi as one of India's leading TIC beneficiaries.

Short descriptiontext

Vimta Labs is a Hyderabad-headquartered, publicly listed Contract Research and Testing Organization serving pharmaceutical, biopharma, food, electronics and industrial manufacturers with cGMP lab services, preclinical/clinical research, biologics testing, food/PSP certification and clinical diagnostics across 15+ Indian cities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices19 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, analytical testing services, product certification services, preclinical and clinical research, laboratory testing services
Industry5 codes
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAKAK
Laboratory Quality & GLP/GCLP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAJAIAM
Laboratory Quality Systems, Accreditation & Proficiency Testing Programs
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
NAICS code3 codes
  • Testing Laboratories and Services541380
  • Testing Laboratories and Services54138
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research and Testing Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research and Testing Services
TypeProfessional Services
Description

Primary revenue stream generated from laboratory testing and contract research services across pharmaceuticals, biologics, food, environment, electrical & electronics, and medical devices. Reported standalone quarterly sales of Rs 109.25 crore (Q4 FY26, +15.68% YoY) and full-year FY26 sales of Rs 407.29 crore (+18.41% YoY).

business-standard.com
2Product Certification Services (Physical Security Products)
TypeLicensing Royalties
Description

Revenue from certification fees including application fees, minimum marking fees, audit fees, and license fees for ATM Safes, Burglary-resistant Safes, Fire & Burglary-resistant Safes, and Fire Resistant Secure Safe Cabinets under NABCB ISO/IEC 17065 accreditation.

vimta.com
3Clinical Diagnostics Services
TypeManaged Services
Description

Revenue from Clinical Reference Lab operations across multiple Hyderabad locations (Sainikpuri, SD Road, Kukatpally, Habsiguda, AS Rao Nagar) and other cities (Chennai, Varanasi, Visakhapatnam, Vijayawada, Bhubaneshwar, Tirupati, Kolkata, Delhi NCR, Noida).

vimta.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Quote-based testing and certification services
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; engagement initiated via contact form or by reaching regional sales personnel.

vimta.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vimta Labs is a Contract Research and Testing Organization (CRO) that provides analytical R&D, testing, and product certification services across multiple industry verticals including pharmaceuticals, biologics, food, environment, electricals & electronics, and physical security products. The company operates cGMP-accredited and NABL/NABCB-accredited laboratories and offers end-to-end services spanning drug discovery, preclinical and clinical research, regulatory testing, and market access certification for manufacturers seeking domestic and global compliance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FY26 sales growth of 18.41% YoY to Rs 407.29 crore
+3 more records
Product overview1 text field

Vimta Labs Limited is a full-service Contract Research and Testing Organization (CRO) headquartered in Hyderabad, India, offering a unified portfolio of analytical testing, preclinical/clinical research, and product certification services across multiple industry verticals rather than a single software product. The platform is structured as an industry-vertical portfolio with shared laboratory infrastructure: Pharmaceutical services (cGMP Laboratory Service, Preclinical Research, Clinical Research) and Biologics & Biosimilars offerings (Testing and CRADS Development) anchor the life-sciences side; while Food, Agriculture, Crop Care, Water & Beverages, Home & Personal Care, Medical Devices, Nutraceuticals, Packaging, Specialty Chemicals, and Environment, Health & Safety testing services provide the consumer and industrial coverage. The Electricals & Electronics portfolio is organised along three axes — By Domain (Consumer Electronics, Medical Devices, Avionics, Automotive, Industrial, IT, Military), By Test (EMI and EMC, Environmental & Reliability, Safety and Performance, Radio Frequency, Physical Security), and By Service Package (BIS CRS Testing, TEC Testing, CE Marking, Fan Testing, Toys Safety, Market Access, EN and BIS Testing for PSP) — and feeds into the NABCB-accredited Certification Services (CE Marking Services, PSP Certification and Global Market Access Testing) operated as per ISO/IEC 17065. Emtac Laboratories Pvt Ltd operates as a wholly amalgamated subsidiary supporting the Electrical & Electronics line of business.

Product and service23 records
1cGMP Laboratory Services
CategoryPharmaceutical Testing
Description

Good Manufacturing Practice (cGMP)-accredited laboratory testing and analytical services for pharmaceutical and biopharmaceutical clients requiring regulatory-compliant data.

2Preclinical Research Services
CategoryDrug Discovery & Development
Description

Preclinical safety and efficacy research services supporting drug development programs for pharmaceutical and biotechnology sponsors.

3Clinical Research Services
CategoryClinical Research
Description

Clinical trial management and bioanalytical services for pharmaceutical and biotechnology sponsors conducting human studies.

4Biologics & Biosimilars Testing and Development (CRADS)
CategoryBiologics Testing
Description

Analytical testing and development services for biologics, biosimilars, and cell-line-based products tailored to biopharma clients.

5Food Testing Services
CategoryFood Safety Testing
Description

Analytical and safety testing of food products for manufacturers, processors, and regulators seeking FSSAI and international compliance.

6Agriculture and Crop Care Testing
CategoryAgriculture Testing
Description

Testing services for agricultural inputs, pesticides, fertilizers, and crop-care products targeting agrochemical manufacturers.

7Water and Beverages Testing
CategoryEnvironmental Testing
Description

Water quality and beverage testing services for bottled water, beverage manufacturers, and municipal/industrial clients.

8Home & Personal Care Testing
CategoryConsumer Product Testing
Description

Safety and quality testing of cosmetics, personal care, and household products for FMCG manufacturers.

9Environment, Health & Safety Services
CategoryEnvironmental Testing
Description

Environmental monitoring, EHS compliance, and workplace safety testing for industrial and infrastructure clients.

10Medical Devices Testing
CategoryMedical Device Testing
Description

Testing of medical devices to applicable regulatory and safety standards for medical device manufacturers.

11Nutraceuticals Testing
CategoryPharmaceutical Testing
Description

Analytical and quality testing of nutraceutical and dietary supplement products for manufacturers.

12Packaging Testing
CategoryPackaging Testing
Description

Testing of packaging materials for safety, compatibility, migration, and regulatory compliance for packaging manufacturers and product companies.

13Specialty Chemicals Testing
CategoryChemical Testing
Description

Analytical testing of specialty and industrial chemicals for chemical manufacturers and downstream users.

14Electricals & Electronics Testing
CategoryElectronics Testing
Description

Product safety and performance testing of electrical and electronic equipment for manufacturers seeking regulatory approvals.

15EMI and EMC Testing
CategoryElectronics Testing
Description

Electromagnetic Interference (EMI) and Electromagnetic Compatibility (EMC) testing for electronics manufacturers targeting regulatory compliance.

16Environmental and Reliability Testing
CategoryElectronics Testing
Description

Reliability, climatic, vibration, and environmental stress testing for electronics and industrial product manufacturers.

17Safety and Performance Testing
CategoryProduct Safety Testing
Description

Product safety and performance testing services including fan, toy, and electrical appliance testing for manufacturers.

18Radio Frequency Testing
CategoryElectronics Testing
Description

RF testing and certification for telecom and wireless equipment manufacturers targeting global market access.

19BIS CRS and TEC Testing
CategoryRegulatory Compliance Testing
Description

Domestic Indian regulatory testing under BIS (Bureau of Indian Standards) CRS scheme and TEC (Telecom Engineering Centre) requirements for electronics and telecom manufacturers.

20CE Marking Certification and Testing
CategoryProduct Certification
Description

CE marking testing and certification support for manufacturers seeking access to the European Union market.

21Physical Security Product (PSP) Testing and Certification
CategoryProduct Certification
Description

Testing and certification of physical security products under EN and BIS standards, including NABCB-accredited certification services for security equipment manufacturers.

22Global Market Access Testing
CategoryProduct Certification
Description

Testing and certification services enabling manufacturers to access international markets across multiple geographies.

23Clinical Diagnostics Services
CategoryClinical Diagnostics
Description

Diagnostic testing services including walk-in clinical lab offerings operated under VClin Bio Labs for individuals and clinical partners.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Through an extensive network of partners across the globe (Notified Body / Telecommunication Certification Body partners), Vimta delivers FCC, Industry Canada, CE Marking and in-country testing requirements (Korea, Brazil) for wireless products; over 30 man-years of experience in Global Market Access.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-08-30
Description

Execution and completion of Business Transfer Agreement (BTA) with Thyrocare Technologies Limited on 30 August 2024. Per a market research note, Thyrocare Technologies Limited acquired Vimta Labs Limited in September 2024 to expand its food diagnostics capabilities and diversify its healthcare portfolio. This represents a major strategic shift in ownership and business positioning.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Public-Private Partnership between Vimta Labs and FSSAI to set, operate and transfer the National Food Laboratory. Vimta operates the National Food Lab at JNPT Township, Sector-3, Mumbai, supporting food safety testing capacity for Indian regulators.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-01-01
Description

Acquisition of Emtac Laboratories Private Limited (announced 2019); subsequent Scheme of Amalgamation of Emtac Laboratories Private Limited with Vimta Labs Limited; NCLT Order dated 23.01.2025 sanctioned the amalgamation. Emtac serves as a subsidiary supporting electronics testing capacity.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global TIC major with strong presence in India across marine, commodities, industry, construction, certification and consumer products testing. Overlaps with Vimta's electrical/electronics testing, certification services and CE marking capabilities.

2Syngene International
TypeDirect peer
Description

India's largest listed Contract Research Organization offering integrated drug discovery, development, and manufacturing services to global pharma. Closest direct peer to Vimta's pharma/biologics CRO business, both featured together as key beneficiaries of India's TIC opportunity.

TypeBroad incumbent
Description

Global TIC company providing quality assurance, testing, inspection and certification across consumer products, electronics, and pharmaceuticals. Directly comparable to Vimta's electronics/EMI-EMC testing and product certification portfolio, with growing India footprint.

TypeBroad incumbent
Description

Global Testing, Inspection and Certification leader operating across pharma, food, environment and electronics verticals. Eurofins Analytical Services India is also a disclosed financial shareholder of Vimta, making it a hybrid competitor-shareholder relationship across overlapping Indian TIC segments.

TypeBroad incumbent
Description

World's largest TIC company offering inspection, verification, testing and certification services globally. Directly comparable to Vimta's electronics testing, EMI/EMC, RF, and food testing lines, with established Indian operations and broader accreditation portfolio.

TypeBroad incumbent
Description

Integrated Contract Development and Manufacturing Organization (CDMO) offering drug substance, drug product, and analytical services globally. Comparable to Vimta's cGMP lab, preclinical and biologics testing capabilities, with substantially larger scale and global footprint.

TypeDirect peer
Description

India-based Contract Research, Development and Manufacturing Organization (CRDMO) offering drug discovery, development, and clinical services to global pharma. Direct Indian CRO peer to Vimta's pharma/biologics preclinical and clinical research business.

TypeBroad incumbent
Description

Global TIC provider with deep expertise in product testing, certification, and auditing across automotive, electronics, medical devices, and industrial sectors. Comparable to Vimta's electrical & electronics, medical device, and CE marking certification offerings.

9Veeda Clinical Research
TypeDirect peer
Description

India-headquartered CRO offering clinical research, bioequivalence, bioanalysis and preclinical services. Direct peer to Vimta's clinical research and bioanalytical testing offerings, both serving Indian and global pharma sponsors.

TypeDirect peer
Description

Indian-listed pharmaceutical CRO/CDMO providing contract manufacturing, analytical services, and API development. Comparable to Vimta's cGMP laboratory services and pharma analytical testing offerings, with overlap in serving generic and innovator drug developers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vimta Labs

Contract Research and Testing Servicesvimta.com

Vimta Labs is a Hyderabad-headquartered, publicly listed Contract Research and Testing Organization serving pharmaceutical, biopharma, food, electronics and industrial manufacturers with cGMP lab services, preclinical/clinical research, biologics testing, food/PSP certification and clinical diagnostics across 15+ Indian cities.

What Vimta Labs does

Vimta Labs Limited is a publicly listed (NSE: VIMTALABS; BSE) Hyderabad-headquartered Contract Research and Testing Organization (CRO) founded on 17 August 1984, operating a nationwide network of accredited laboratories across pharmaceuticals, biologics, food, water, electricals & electronics, environment/health & safety, medical devices and clinical diagnostics. The company serves pharmaceutical and biopharma manufacturers with cGMP laboratory services, preclinical and clinical research support, and biologics/biosimilars testing and development (CRADS), while its food testing arm operates India's National Food Laboratory at JNPT Mumbai under a Public-Private Partnership with FSSAI and runs food labs in 8+ cities. The electricals & electronics testing business — organized by Domain (consumer electronics, avionics, automotive, military), by Test (EMI/EMC, RF, environmental reliability, physical security), and by Service Package (BIS CRS, TEC, CE Marking) — is anchored by Vimta's status as the only NABCB-accredited certification body in India for Physical Security Products under ISO/IEC 17065 and the first-in-India NABL-accredited PSP test facility. Emtac Laboratories Private Limited, acquired in 2019-20, was amalgamated into Vimta via NCLT order dated 23 January 2025 to consolidate electronics testing capacity.

Vimta earns revenue primarily through professional services (contract research and laboratory testing) billed on a quote-based, project-specific basis with pay-as-you-go cadence across enterprise field sales channels; a secondary licensing-style revenue stream comes from PSP product certification fees (application, minimum marking, audit and licence fees); and a managed-services revenue stream is generated from walk-in clinical diagnostics labs. The GTM motion combines direct regional sales personnel in 15+ Indian cities, active participation in global industry conferences (CPHI Milan, Eurotox, DCAT, CAC, Chemspec), institutional investor engagement through quarterly earnings calls, and regulatory partnerships including the FSSAI PPP. Pricing is not publicly disclosed; engagement is initiated via regional sales contacts or web inquiry forms.

In August 2024, Vimta executed and completed a Business Transfer Agreement with Thyrocare Technologies Limited, divesting its food diagnostics business to refocus on the core CRO and certification platform. For FY2025-26, Vimta reported standalone sales of Rs 407.29 crore (up 18.41% YoY) and net profit of Rs 77.51 crore (up 15.10%), with Q4 FY26 sales of Rs 109.25 crore (up 15.68%) — placing the company within India's TIC market that is projected to grow from USD 7.9 billion in 2025 to nearly USD 10.9 billion by 2034. The company has 1,001-5,000 employees, is led by Executive Chairman Dr. S. P. Vasireddi (re-appointed effective 1 July 2026), and is recognized alongside Syngene International and Tata Elxsi as one of India's leading TIC beneficiaries.

Vimta Labs firmographics

Firmographics
Name
Vimta Labs
Legal name
Vimta Labs Limited
Website
https://vimta.com
Company type
Public
Founded year
1984
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Vimta Labs is a Hyderabad-headquartered, publicly listed Contract Research and Testing Organization serving pharmaceutical, biopharma, food, electronics and industrial manufacturers with cGMP lab services, preclinical/clinical research, biologics testing, food/PSP certification and clinical diagnostics across 15+ Indian cities.
Ownership category
akta.pro rank

Vimta Labs industry classification

Industry
Product category
Contract Research and Testing Services
NAICS
Testing Laboratories and Services (541380), Testing Laboratories and Services (54138), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAKAK
Laboratory Quality & GLP/GCLP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAJAIAM
Laboratory Quality Systems, Accreditation & Proficiency Testing Programs
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Contract research organization
  • Analytical testing services
  • Product certification services
  • Preclinical and clinical research
  • Laboratory testing services

Where Vimta Labs is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices19 records

Markets served

Vimta Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research and Testing Services: Primary revenue stream generated from laboratory testing and contract research services across pharmaceuticals, biologics, food, environment, electrical & electronics, and medical devices. Reported standalone quarterly sales of Rs 109.25 crore (Q4 FY26, +15.68% YoY) and full-year FY26 sales of Rs 407.29 crore (+18.41% YoY).
  2. Product Certification Services (Physical Security Products): Revenue from certification fees including application fees, minimum marking fees, audit fees, and license fees for ATM Safes, Burglary-resistant Safes, Fire & Burglary-resistant Safes, and Fire Resistant Secure Safe Cabinets under NABCB ISO/IEC 17065 accreditation.
  3. Clinical Diagnostics Services: Revenue from Clinical Reference Lab operations across multiple Hyderabad locations (Sainikpuri, SD Road, Kukatpally, Habsiguda, AS Rao Nagar) and other cities (Chennai, Varanasi, Visakhapatnam, Vijayawada, Bhubaneshwar, Tirupati, Kolkata, Delhi NCR, Noida).

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based testing and certification services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Vimta Labs product offering

Product offering

Core offering

Vimta Labs is a Contract Research and Testing Organization (CRO) that provides analytical R&D, testing, and product certification services across multiple industry verticals including pharmaceuticals, biologics, food, environment, electricals & electronics, and physical security products. The company operates cGMP-accredited and NABL/NABCB-accredited laboratories and offers end-to-end services spanning drug discovery, preclinical and clinical research, regulatory testing, and market access certification for manufacturers seeking domestic and global compliance.

Product overview

Vimta Labs Limited is a full-service Contract Research and Testing Organization (CRO) headquartered in Hyderabad, India, offering a unified portfolio of analytical testing, preclinical/clinical research, and product certification services across multiple industry verticals rather than a single software product. The platform is structured as an industry-vertical portfolio with shared laboratory infrastructure: Pharmaceutical services (cGMP Laboratory Service, Preclinical Research, Clinical Research) and Biologics & Biosimilars offerings (Testing and CRADS Development) anchor the life-sciences side; while Food, Agriculture, Crop Care, Water & Beverages, Home & Personal Care, Medical Devices, Nutraceuticals, Packaging, Specialty Chemicals, and Environment, Health & Safety testing services provide the consumer and industrial coverage. The Electricals & Electronics portfolio is organised along three axes — By Domain (Consumer Electronics, Medical Devices, Avionics, Automotive, Industrial, IT, Military), By Test (EMI and EMC, Environmental & Reliability, Safety and Performance, Radio Frequency, Physical Security), and By Service Package (BIS CRS Testing, TEC Testing, CE Marking, Fan Testing, Toys Safety, Market Access, EN and BIS Testing for PSP) — and feeds into the NABCB-accredited Certification Services (CE Marking Services, PSP Certification and Global Market Access Testing) operated as per ISO/IEC 17065. Emtac Laboratories Pvt Ltd operates as a wholly amalgamated subsidiary supporting the Electrical & Electronics line of business.

Differentiator

Problem solved

Functional benefit

Products and services

  • cGMP Laboratory Services Good Manufacturing Practice (cGMP)-accredited laboratory testing and analytical services for pharmaceutical and biopharmaceutical clients requiring regulatory-compliant data.
  • Preclinical Research Services Preclinical safety and efficacy research services supporting drug development programs for pharmaceutical and biotechnology sponsors.
  • Clinical Research Services Clinical trial management and bioanalytical services for pharmaceutical and biotechnology sponsors conducting human studies.
  • Biologics & Biosimilars Testing and Development (CRADS) Analytical testing and development services for biologics, biosimilars, and cell-line-based products tailored to biopharma clients.
  • Food Testing Services Analytical and safety testing of food products for manufacturers, processors, and regulators seeking FSSAI and international compliance.
  • Agriculture and Crop Care Testing Testing services for agricultural inputs, pesticides, fertilizers, and crop-care products targeting agrochemical manufacturers.
  • Water and Beverages Testing Water quality and beverage testing services for bottled water, beverage manufacturers, and municipal/industrial clients.
  • Home & Personal Care Testing Safety and quality testing of cosmetics, personal care, and household products for FMCG manufacturers.
  • Environment, Health & Safety Services Environmental monitoring, EHS compliance, and workplace safety testing for industrial and infrastructure clients.
  • Medical Devices Testing Testing of medical devices to applicable regulatory and safety standards for medical device manufacturers.
  • Nutraceuticals Testing Analytical and quality testing of nutraceutical and dietary supplement products for manufacturers.
  • Packaging Testing Testing of packaging materials for safety, compatibility, migration, and regulatory compliance for packaging manufacturers and product companies.
  • Specialty Chemicals Testing Analytical testing of specialty and industrial chemicals for chemical manufacturers and downstream users.
  • Electricals & Electronics Testing Product safety and performance testing of electrical and electronic equipment for manufacturers seeking regulatory approvals.
  • EMI and EMC Testing Electromagnetic Interference (EMI) and Electromagnetic Compatibility (EMC) testing for electronics manufacturers targeting regulatory compliance.
  • Environmental and Reliability Testing Reliability, climatic, vibration, and environmental stress testing for electronics and industrial product manufacturers.
  • Safety and Performance Testing Product safety and performance testing services including fan, toy, and electrical appliance testing for manufacturers.
  • Radio Frequency Testing RF testing and certification for telecom and wireless equipment manufacturers targeting global market access.
  • BIS CRS and TEC Testing Domestic Indian regulatory testing under BIS (Bureau of Indian Standards) CRS scheme and TEC (Telecom Engineering Centre) requirements for electronics and telecom manufacturers.
  • CE Marking Certification and Testing CE marking testing and certification support for manufacturers seeking access to the European Union market.
  • Physical Security Product (PSP) Testing and Certification Testing and certification of physical security products under EN and BIS standards, including NABCB-accredited certification services for security equipment manufacturers.
  • Global Market Access Testing Testing and certification services enabling manufacturers to access international markets across multiple geographies.
  • Clinical Diagnostics Services Diagnostic testing services including walk-in clinical lab offerings operated under VClin Bio Labs for individuals and clinical partners.

Quantifiable outcome

  • FY26 sales growth of 18.41% YoY to Rs 407.29 crore
  • +3 more outcomes

Companies that use Vimta Labs

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Vimta Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vimta Labs partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Global Market Access Partners (Notified Body / Telecommunication Certification Body partners)coreTechnology or Integration · 1 January 2025Through an extensive network of partners across the globe (Notified Body / Telecommunication Certification Body partners), Vimta delivers FCC, Industry Canada, CE Marking and in-country testing requirements (Korea, Brazil) for wireless products; over 30 man-years of experience in Global Market Access.
  • Thyrocare Technologies LimitedflagshipStrategic or Co-development Partner · 30 August 2024Execution and completion of Business Transfer Agreement (BTA) with Thyrocare Technologies Limited on 30 August 2024. Per a market research note, Thyrocare Technologies Limited acquired Vimta Labs Limited in September 2024 to expand its food diagnostics capabilities and diversify its healthcare portfolio. This represents a major strategic shift in ownership and business positioning.
  • FSSAI (Food Safety and Standards Authority of India)flagshipStrategic or Co-development Partner · 1 January 2024Public-Private Partnership between Vimta Labs and FSSAI to set, operate and transfer the National Food Laboratory. Vimta operates the National Food Lab at JNPT Township, Sector-3, Mumbai, supporting food safety testing capacity for Indian regulators.
  • Emtac Laboratories Private LimitedcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2019Acquisition of Emtac Laboratories Private Limited (announced 2019); subsequent Scheme of Amalgamation of Emtac Laboratories Private Limited with Vimta Labs Limited; NCLT Order dated 23.01.2025 sanctioned the amalgamation. Emtac serves as a subsidiary supporting electronics testing capacity.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Vimta Labs competitors and assessment

Company assessment

Broad incumbents

  • Bureau Veritas: Global TIC major with strong presence in India across marine, commodities, industry, construction, certification and consumer products testing. Overlaps with Vimta's electrical/electronics testing, certification services and CE marking capabilities.
  • Intertek: Global TIC company providing quality assurance, testing, inspection and certification across consumer products, electronics, and pharmaceuticals. Directly comparable to Vimta's electronics/EMI-EMC testing and product certification portfolio, with growing India footprint.
  • Eurofins Scientific: Global Testing, Inspection and Certification leader operating across pharma, food, environment and electronics verticals. Eurofins Analytical Services India is also a disclosed financial shareholder of Vimta, making it a hybrid competitor-shareholder relationship across overlapping Indian TIC segments.
  • SGS: World's largest TIC company offering inspection, verification, testing and certification services globally. Directly comparable to Vimta's electronics testing, EMI/EMC, RF, and food testing lines, with established Indian operations and broader accreditation portfolio.
  • Piramal Pharma Solutions: Integrated Contract Development and Manufacturing Organization (CDMO) offering drug substance, drug product, and analytical services globally. Comparable to Vimta's cGMP lab, preclinical and biologics testing capabilities, with substantially larger scale and global footprint.
  • TUV SUD: Global TIC provider with deep expertise in product testing, certification, and auditing across automotive, electronics, medical devices, and industrial sectors. Comparable to Vimta's electrical & electronics, medical device, and CE marking certification offerings.

Direct peers

  • Syngene International: India's largest listed Contract Research Organization offering integrated drug discovery, development, and manufacturing services to global pharma. Closest direct peer to Vimta's pharma/biologics CRO business, both featured together as key beneficiaries of India's TIC opportunity.
  • Sai Life Sciences: India-based Contract Research, Development and Manufacturing Organization (CRDMO) offering drug discovery, development, and clinical services to global pharma. Direct Indian CRO peer to Vimta's pharma/biologics preclinical and clinical research business.
  • Veeda Clinical Research: India-headquartered CRO offering clinical research, bioequivalence, bioanalysis and preclinical services. Direct peer to Vimta's clinical research and bioanalytical testing offerings, both serving Indian and global pharma sponsors.
  • Neuland Laboratories: Indian-listed pharmaceutical CRO/CDMO providing contract manufacturing, analytical services, and API development. Comparable to Vimta's cGMP laboratory services and pharma analytical testing offerings, with overlap in serving generic and innovator drug developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vimta Labs social profiles

Digital presence

Vimta Labs compliance and trust

Trust signal

Compliance9 records

Vimta Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vimta Labs leadership team

Management profile

Number of profiles

Profiles7 records

Vimta Labs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vimta Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vimta Labs M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vimta Labs

What does Vimta Labs do?

Vimta Labs is a Contract Research and Testing Organization (CRO) that provides analytical R&D, testing, and product certification services across multiple industry verticals including pharmaceuticals, biologics, food, environment, electricals & electronics, and physical security products. The company operates cGMP-accredited and NABL/NABCB-accredited laboratories and offers end-to-end services spanning drug discovery, preclinical and clinical research, regulatory testing, and market access certification for manufacturers seeking domestic and global compliance.

Is Vimta Labs a public or private company?

Vimta Labs is a public company. It is classified as public and is currently operating.

When was Vimta Labs founded?

Vimta Labs was founded in 1984. It employs 1,001 to 5,000 people.

Where is Vimta Labs based?

Vimta Labs is headquartered in Hyderabad, India, in the Asia region.

How does Vimta Labs make money?

Three revenue lines are on record. Contract Research and Testing Services are the primary driver. The others are product Certification Services (Physical Security Products) and clinical Diagnostics Services.

Who are Vimta Labs's main competitors?

Broad incumbents on record are Bureau Veritas, Intertek, Eurofins Scientific, SGS, Piramal Pharma Solutions and TUV SUD. Direct peers are Syngene International, Sai Life Sciences, Veeda Clinical Research and Neuland Laboratories.

Does Vimta Labs have an API?

No public API is recorded for Vimta Labs.

What industry is Vimta Labs in?

Vimta Labs's product category is Contract Research and Testing Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 541380 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewVimta Labs Q2 2027 Earnings Call Is LiveVimta Labs' Q2 2027 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending can move markets.Business StandardCARE Ratings reaffirms ratings of Vimta Labs at 'A/A1' with 'stable' outlookCARE Ratings reaffirmed Vimta Labs' long-term rating at 'CARE A' with a stable outlook, and its short-term rating at 'CARE A1'. The company reported a PBILDT margin of 35.26% and PAT margin of 18.86% in FY26, with net profit rising 11.38% to Rs 21.04 crore in Q1 FY27. Its Biologics segment, still in development, is expected to generate revenue by FY27-end.NDTV ProfitStocks To Watch Today: Aurobindo Pharma, Vimta Labs, Natco Pharma, Power Grid, Apollo Micro System & MoreThis article lists several Indian companies likely to be in focus during the trading session on Monday, detailing recent corporate announcements and regulatory updates. Key developments include Aurobindo Pharma and Natco Pharma receiving US FDA inspection results, Power Grid winning a transmission project, and Urban Company suing Kent RO over advertising claims.MintBuy or sell: Gift Nifty signals muted start! Vaishali Parekh recommends three intraday stocks to buy today | Stock Market NewsThe Indian stock market is expected to open with a slight positive bias, influenced by global cues and falling energy prices. Analyst Vaishali Parekh predicts consolidation around current levels with targets of 25,000 and 25,500 for the Nifty 50, and suggests buy signals for stocks NTPC, GNFC, and Vimta Labs.Investing.comVimta Q1 FY27 slides: 14% revenue growth, biologics launch By Investing.comVimta Labs Limited reported Q1 FY27 total income of Rs 1,129 million, representing 13.7% year-over-year growth with EBITDA of Rs 411 million (36.4% margin) and PAT of Rs 210 million (18.6% margin). The company successfully operationalized its new biologics contract research and development facility and secured its first order in this segment, positioning for future growth in high-value life sciences services.Investing.comEarnings call transcript: Vimta Labs Q1 2026 shares fall 5.4% after solid growth By Investing.comVimta Labs Limited reported double-digit revenue and profit growth for Q1 FY2027 (quarter ended June 30, 2026), with total income rising 13.7% year-over-year to INR 1,129 million and profit after tax up 11.4% to INR 210 million. Despite the solid financial performance, the company's stock fell 5.4% to $529, reflecting investor concerns over margin pressure in certain segments and weakness in food testing due to geopolitical tensions. Management maintained its growth target of INR 500 crores in annual revenue and confirmed the operational launch of its new biologics contract research and development facility, which has secured its first order.Business StandardVimta Labs standalone net profit rises 11.38% in the June 2026 quarterVimta Labs reported an 11.38% increase in standalone net profit for the quarter ended June 2026, reaching Rs 21.04 crore compared to Rs 18.89 crore in the same quarter of the previous year. Sales for the period rose 11.80% to Rs 109.07 crore from Rs 97.56 crore, while operating profit margin remained stable at 34.21%. The financial results were powered by Capital Market - Live News.ScanXVimta Labs Q1FY27 net profit rises to ₹210.42 millionVimta Labs reported a year-on-year increase in Q1FY27 net profit to ₹210.42 million, driven by revenue growth to ₹1,090.74 million and EBITDA improvement to ₹373.38 million, though EBITDA margins dipped slightly to 34.24%. The Board approved the unaudited financial results on July 20, 2026, following an analyst and investor conference call to discuss the quarterly performance. The company, a listed contract research and testing services provider, continues to show year-over-year growth in its core financial metrics.ScanXVimta Labs pays ₹2 dividend for FY26Vimta Labs Limited distributed a dividend of ₹2 per share for FY26 on July 4, 2026, following shareholder approval at the Annual General Meeting. The payout represents a return of capital to shareholders but raises questions about the company's capital allocation strategy going forward. No forward-looking guidance or broader strategic context was provided in the article.NDTV ProfitTata Tech, Vimta Labs, Capital Small Finance Bank, GHCL Dividend Record Date: Last Day To Buy Shares To QualifyMultiple Indian companies including Tata Technologies, GHCL, HDB Financial Services, Vimta Labs, JSW Infrastructure, Capital Small Finance Bank, Swastika Investmart, Monika Alcobev, and eMudhra have set June 18 as their dividend record date, making June 17 the last trading day for retail investors to purchase shares and qualify for the payouts. GHCL Ltd. announced the highest dividend at Rs 12 per share, while Tata Technologies declared a combined final and special dividend totaling Rs 11.70 per share. Under India's T+1 settlement cycle, investors must own shares by June 17 to be eligible, as share purchases on the record date do not qualify for dividend payments.